Post-Procedure Care and Compliance Agreement
This document must be signed before enhancement procedures. Review carefully with your Enhancement Specialist.
POST-PROCEDURE CARE AND COMPLIANCE AGREEMENT
Document Version: 2.8 Effective Date: April 1, 2025 Document ID: UL-LEGAL-PP-028
PREAMBLE
This Post-Procedure Care and Compliance Agreement (“Agreement”) establishes the obligations of the enhanced individual (“Recipient”) following enhancement procedures performed by Unzyme Laboratories Corporation (“Unzyme Laboratories”).
Compliance with this Agreement is mandatory and constitutes a condition of ongoing enhancement support and warranty coverage.
ARTICLE I: MANDATORY MAINTENANCE
Section 1.1: Scheduled Appointments
Recipient agrees to attend all scheduled maintenance appointments, including:
a) Initial Follow-Up: Within 7 days post-procedure b) Calibration Sessions: At 14 days, 30 days, 90 days, and annually thereafter c) Emergency Appointments: Within 24 hours of notification for urgent issues d) Recall Appointments: As required for safety-related updates or modifications
Section 1.2: Consequences of Missed Appointments
Failure to attend mandatory appointments may result in:
a) Automatic entry into Limited Function Mode for safety purposes b) Suspension of warranty coverage c) Billing for emergency interventions required due to preventable malfunction d) Termination of Enhancement Support Agreement
Section 1.3: Appointment Rescheduling
Appointments may be rescheduled with minimum 48 hours notice. Repeated rescheduling (3+ times for a single appointment) will be treated as non-compliance.
ARTICLE II: HOME CARE COMPLIANCE
Section 2.1: Prescribed Care Protocols
Recipient agrees to follow all home care protocols provided by Enhancement Support Specialists, including:
a) Medication adherence b) Activity restrictions c) Wound care and hygiene d) System operation guidelines e) Dietary and lifestyle recommendations
Section 2.2: Prohibited Activities
Without prior written authorization, Recipient shall not:
a) Undergo MRI imaging (risk of implant damage, projectile hazard) b) Participate in high-impact sports or activities exceeding enhancement ratings c) Enter strong electromagnetic fields (industrial equipment, power facilities) d) Travel to altitudes exceeding 15,000 feet without pressure compensation e) Undergo other medical procedures without disclosing enhancement status f) Consume substances contraindicated for enhanced individuals
Section 2.3: Required Disclosures
Recipient must disclose enhancement status to:
a) All medical providers prior to treatment b) Emergency responders during emergency situations c) Security personnel when requested d) Any party when required by law
ARTICLE III: SYSTEM UPDATES AND MODIFICATIONS
Section 3.1: Mandatory Updates
Recipient agrees to accept all firmware updates and system modifications transmitted by Unzyme Laboratories. These updates:
a) Are mandatory, not optional b) May modify system behavior without separate consent c) Occur automatically during sleep cycles when possible d) May require facility visits for significant modifications
Section 3.2: Prohibited Modifications
Recipient shall not:
a) Attempt to modify, hack, or alter enhancement systems b) Install unauthorized software or firmware c) Connect enhancement systems to unauthorized devices d) Seek modification services from third parties e) Reverse engineer any aspect of the enhancement system
Section 3.3: Consequences of Unauthorized Modification
Unauthorized modification results in:
a) Immediate warranty termination b) Termination of support services c) Potential remote system deactivation for safety d) Legal action for violation of intellectual property rights e) Liability for any resulting harm to self or others
ARTICLE IV: REPORTING REQUIREMENTS
Section 4.1: Mandatory Reporting
Recipient must report the following within 24 hours:
a) Medical Events: Any illness, injury, or hospitalization b) System Anomalies: Unusual behavior, errors, or malfunctions c) Psychological Concerns: Significant mood changes, identity concerns, or cognitive disturbances d) Incidents: Any incident where enhancement capabilities caused harm or potential harm e) Legal Matters: Any legal proceedings involving enhancement capabilities
Section 4.2: Reporting Methods
Reports should be submitted via:
- Patient Portal (preferred)
- Phone: 1-800-UNZYME-1
- Email: reporting@unzymelaboratories.com
- In person at any Unzyme Laboratories facility
Section 4.3: Failure to Report
Failure to report required events may result in:
- Warranty claim denial
- Liability for preventable complications
- Service termination
ARTICLE V: EMERGENCY PROTOCOLS
Section 5.1: Emergency Response Authorization
Recipient authorizes Unzyme Laboratories to:
a) Remotely access enhancement systems during emergencies b) Modify system operation to ensure safety c) Deactivate systems if necessary to prevent harm d) Share necessary information with emergency responders e) Dispatch emergency personnel to Recipient’s location
Section 5.2: Emergency Cooperation
During emergencies, Recipient agrees to:
a) Cooperate with Unzyme Laboratories emergency instructions b) Proceed to designated facility when directed c) Remain in place if instructed pending emergency response d) Provide access to enhancement systems for emergency diagnosis
Section 5.3: Emergency Suppression
Recipient acknowledges that emergency suppression (voluntary or involuntary) may be necessary and consents to such intervention when:
a) System malfunction threatens safety b) Recipient’s behavior poses risk to self or others c) Emergency responders require system deactivation d) Unzyme Laboratories determines intervention necessary for safety
ARTICLE VI: BEHAVIORAL COMPLIANCE
Section 6.1: Responsible Use
Recipient agrees to use enhancement capabilities responsibly, including:
a) Compliance with all applicable laws b) Avoidance of harm to others c) Appropriate use of enhanced strength, perception, or cognition d) Ethical application of enhanced capabilities
Section 6.2: Monitoring Cooperation
Recipient agrees to cooperate with Unzyme Laboratories behavioral monitoring programs, including:
a) Periodic psychological assessments b) Review of behavioral data collected by enhancement systems c) Interviews and consultations when requested d) Participation in safety studies
Section 6.3: Intervention Cooperation
If Unzyme Laboratories determines intervention is necessary due to behavioral concerns, Recipient agrees to:
a) Participate in recommended counseling or therapy b) Accept temporary capability limitations if imposed for safety c) Submit to enhanced monitoring d) Comply with behavioral modification recommendations
ARTICLE VII: TERM AND TERMINATION
Section 7.1: Duration
This Agreement remains in effect for the lifetime of the enhancement system(s), or until all enhancement systems are completely removed.
Section 7.2: Termination by Unzyme Laboratories
Unzyme Laboratories may terminate this Agreement and related services for:
a) Material breach of this Agreement b) Failure to maintain compliance c) Behavior that poses safety risks d) Fraudulent enrollment or misrepresentation
Section 7.3: Effect of Termination
Upon termination:
a) Warranty coverage ends immediately b) Support services are discontinued c) Recipient remains responsible for enhancement maintenance d) Data collection continues per Data Collection Notice e) This Agreement’s liability limitations survive termination
ACKNOWLEDGMENT AND SIGNATURE
I HAVE READ AND UNDERSTAND THIS AGREEMENT. I AGREE TO COMPLY WITH ALL REQUIREMENTS AND UNDERSTAND THAT FAILURE TO COMPLY MAY RESULT IN SERVICE TERMINATION, WARRANTY VOIDING, AND OTHER CONSEQUENCES.
Recipient Signature: _________________________________
Printed Name: _________________________________
Date: _________________________________
Enhancement Specialist: _________________________________
Specialist Signature: _________________________________
Retain copy for your records. Questions may be directed to your Enhancement Support Specialist.